Cisplatin Export Market Intelligence: India's 233 Suppliers Shipping to 130 Countries — TransData Nexus 2026

Q: Who are the top cisplatin exporters from India?

The top cisplatin exporters from India are: 1. FRESENIUS KABI ONCOLOGY LIMITED — $2.8M (21.5% market share); 2. VENUS REMEDIES LIMITED — $1.7M (12.9% market share); 3. INTAS PHARMACEUTICALS LIMITED — $1.5M (11.3% market share); 4. NV REMEDIES PRIVATE LIMITED — $1.3M (10.1% market share); 5. MYLAN LABORATORIES LIMITED — $775.1K (6.0% market share). Together they account for 61.9% of India's total cisplatin export value.

Q: What is the total export value of cisplatin from India?

The total export value of cisplatin from India is $12.8M USD, recorded across 1,701 shipment transactions from 233 active exporters to 130 destination countries. The average shipment value is $7.6K.

Q: Which countries import cisplatin from India?

India exports cisplatin to 130 countries worldwide. The top importing countries are: TAIWAN (12.4% share, $1.6M), HUNGARY (10.7% share, $1.4M), FRANCE (7.2% share, $922.2K), UNITED STATES (6.9% share, $891.1K), THAILAND (6.8% share, $876.5K). These five markets account for 44.0% of total export value.

Q: What is the HS code for cisplatin exports from India?

The primary HS code for cisplatin exports from India is 30049047. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of cisplatin exports from India?

The average unit price for cisplatin exports from India is $4.29 USD per unit, with prices ranging from $0.01 to $525.99 depending on formulation, packaging, and order volume. The total market is valued at $12.8M across 1,701 shipments.

Q: Which ports handle cisplatin exports from India?

The primary ports for cisplatin exports from India are SAHAR AIR CARGO ACC (INBOM4) (17.6% of shipments), SAHAR AIR (16.5% of shipments), DELHI AIR CARGO ACC (INDEL4) (15.3% of shipments), DELHI AIR (13.9% of shipments), Bombay Air (6.1% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cisplatin?

India is one of the world's leading exporters of cisplatin due to its large base of 233 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cisplatin to 130 countries, demonstrating 67% global market coverage.

Q: What certifications do Indian cisplatin exporters need?

Indian cisplatin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cisplatin from India?

There are 584 registered buyers importing cisplatin from India, spread across 130 countries. The repeat buyer rate is 50.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cisplatin supplier from India?

FRESENIUS KABI ONCOLOGY LIMITED is the leading cisplatin exporter from India with a market share of 21.5% and total export value of $2.8M across 60 shipments. The top 5 suppliers together control 61.9% of total export value.

Suresh Sormare

Cisplatin

India Pharmaceutical Trade Intelligence

$12.8M233 Suppliers130 CountriesHS 30049047

ExportsIndia → TAIWAN12.4%India → HUNGARY10.7%

ImportsGERMANY → India$9.5K UNITED STATES → India$2.3K

#1 Supplier: FRESENIUS KABI

Cisplatin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cisplatin to the World

Between 2022 and 2026, India exported $12.8M worth of cisplatin across 1,701 verified shipments to 130 countries — covering 67% of world markets in the Oncology segment. The largest destination is TAIWAN (12.4%). FRESENIUS KABI ONCOLOGY LIMITED leads with a 21.5% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049047

Cisplatin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cisplatin export data snapshot — $12.8M · 233 exporters · 130 countriesTransData Nexus · Indian Customs Data

Top Cisplatin Exporters from India

233 active exporters · Ranked by export value

View all 233 →

Top Cisplatin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	FRESENIUS KABI ONCOLOGY LIMITED	$2.8M	60	8	21.5%
2	VENUS REMEDIES LIMITED

Top Countries Importing Cisplatin from India

130 destination markets · Ranked by import value

All 130 countries →

Top Countries Importing Cisplatin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	TAIWAN	$1.6M	12.4%
2	HUNGARY	$1.4M	10.7%
3	FRANCE	$922.2K	7.2%
4	UNITED STATES	$891.1K	6.9%
5	THAILAND	$876.5K	6.8%
6	COLOMBIA	$567.7K	4.4%
7	VIETNAM	$475.7K	3.7%
8	MALAYSIA	$397.7K	3.1%
9	MYANMAR	$375.8K	2.9%
10	PHILIPPINES	$302.8K	2.4%

TAIWAN is India's largest cisplatin export destination, absorbing 12.4% of total exports worth $1.6M. The top 5 importing countries — TAIWAN, HUNGARY, FRANCE, UNITED STATES, THAILAND — together account for 44.0% of India's total cisplatin export value. The remaining 125 destination countries collectively receive the other 56.0%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Cisplatin to India?

6 origin countries · Total import value: $14.2K

India imports cisplatin from 6 countries with a combined import value of $14.2K. The largest supplier is GERMANY ($9.5K, 4 shipments), followed by UNITED STATES and BELGIUM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cisplatin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$9.5K	4	67.2%
2	UNITED STATES	$2.3K	12	16.5%
3	BELGIUM	$1.8K	5	12.6%
4	AUSTRIA	$352	2	2.5%
5	UNITED KINGDOM	$160	2	1.1%
6	THAILAND	$11	1	0.1%

GERMANY is the largest supplier of cisplatin to India, accounting for 67.2% of total import value. The top 5 origin countries — GERMANY, UNITED STATES, BELGIUM, AUSTRIA, UNITED KINGDOM — together supply 99.9% of India's cisplatin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Cisplatin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, cisplatin is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The presence of numerous approved ANDAs indicates a competitive market with multiple generic manufacturers. The FDA's regulatory pathway for cisplatin involves rigorous evaluation of bioequivalence and manufacturing standards to ensure safety and efficacy. Given that 6.9% of India's cisplatin exports are directed to the U.S., Indian exporters must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and potential inspections. As of March 2026, there are no active FDA import alerts specifically targeting cisplatin, suggesting that Indian exporters are maintaining compliance with U.S. regulatory standards.

2EU & UK Regulatory Framework

In the European Union, cisplatin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA evaluates applications for generic medicines to ensure they meet EU standards for quality, safety, and efficacy. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of medicines, including cisplatin. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers supplying cisplatin to these markets. With Hungary and France accounting for 10.7% and 7.2% of India's cisplatin exports respectively, adherence to these regulatory frameworks is crucial for market access.

3WHO Essential Medicines & Global Standards

Cisplatin is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its importance in global cancer treatment protocols. The WHO Model List serves as a guide for countries to develop their own national essential medicines lists, promoting access to essential treatments. Additionally, cisplatin formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different regions.

4India Regulatory Classification

In India, cisplatin is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including cisplatin, to ensure affordability. As of March 2026, the ceiling price for cisplatin is set by the NPPA, reflecting the government's commitment to making essential cancer treatments accessible. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring that domestic needs are met before permitting exports.

5Patent & Exclusivity Status

The primary patents for cisplatin have long expired, leading to a robust generic market with multiple manufacturers producing the drug. This generic competition has contributed to the affordability and widespread availability of cisplatin globally.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of cisplatin in the 24th edition. This reaffirms its critical role in cancer treatment protocols worldwide. In January 2026, the NPPA revised the ceiling price for cisplatin, reflecting adjustments to manufacturing costs and market dynamics. This revision aims to balance affordability for patients with sustainable pricing for manufacturers. In February 2026, the CDSCO issued updated guidelines for the export of pharmaceutical products, including cisplatin, emphasizing the need for compliance with international quality standards to facilitate smoother export processes. In March 2026, the FDA approved a new generic version of cisplatin, further increasing competition in the U.S. market and potentially impacting export dynamics for Indian manufacturers. In April 2026, the EMA conducted a review of cisplatin-containing products, reaffirming their benefit-risk balance and ensuring continued availability in the European market.

These developments highlight the dynamic regulatory landscape for cisplatin, emphasizing the importance of continuous compliance and adaptation to maintain market access and competitiveness.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Cisplatin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

The production of Cisplatin relies heavily on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, a major API manufacturer, often depends on imports from China for KSMs due to cost advantages and established supply chains. This dependency introduces vulnerabilities, as any disruption in Chinese supply—be it from regulatory changes, environmental policies, or geopolitical tensions—can significantly affect India's ability to produce and export Cisplatin. For instance, in June 2025, environmental inspections in China led to the temporary shutdown of several chemical plants, causing a ripple effect that delayed API shipments to India and subsequently impacted Cisplatin production schedules.

2Supplier Concentration & Single-Source Risk

The Cisplatin export market from India is notably concentrated. The top five exporters—Fresenius Kabi Oncology Limited (21.5% share), Venus Remedies Limited (12.9%), Intas Pharmaceuticals Limited (11.3%), NV Remedies Private Limited (10.1%), and Mylan Laboratories Limited (6.0%)—collectively account for 61.9% of total exports. This concentration poses a single-source risk; any operational or financial issues within these key companies could disrupt the global supply of Cisplatin. To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in March 2020, aiming to boost domestic API production and reduce reliance on imports. While this initiative has encouraged diversification, its full impact on reducing supplier concentration in the Cisplatin market remains to be seen.

Access Complete Cisplatin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,701 transactions across 130 markets.

Request Demo View Pricing

Frequently Asked Questions — Cisplatin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cisplatin exporters from India?

The leading cisplatin exporters from India are FRESENIUS KABI ONCOLOGY LIMITED, VENUS REMEDIES LIMITED, INTAS PHARMACEUTICALS LIMITED, and 11 others. FRESENIUS KABI ONCOLOGY LIMITED leads with 21.5% market share ($2.8M). The top 5 suppliers together control 61.9% of total export value.

What is the total export value of cisplatin from India?

The total export value of cisplatin from India is $12.8M, recorded across 1,701 shipments from 233 active exporters to 130 countries. The average shipment value is $7.6K.

Which countries import cisplatin from India?

India exports cisplatin to 130 countries. The top importing countries are TAIWAN (12.4%), HUNGARY (10.7%), FRANCE (7.2%), UNITED STATES (6.9%), THAILAND (6.8%), which together account for 44.0% of total export value.

What is the HS code for cisplatin exports from India?

The primary HS code for cisplatin exports from India is 30049047. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cisplatin

Cisplatin

How India Exports Cisplatin to the World

Top Cisplatin Exporters from India

Top Countries Importing Cisplatin from India

Who Supplies Cisplatin to India?

Quick Facts

Related Oncology

Related Analysis

Need Details?

Regulatory Landscape — Cisplatin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Cisplatin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cisplatin Trade Intelligence

Frequently Asked Questions — Cisplatin Exports from India

Who are the top cisplatin exporters from India?

What is the total export value of cisplatin from India?

Which countries import cisplatin from India?

What is the HS code for cisplatin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cisplatin exports from India?

Which ports handle cisplatin exports from India?

Why is India a leading exporter of cisplatin?

What certifications do Indian cisplatin exporters need?

How many buyers import cisplatin from India?

What is the market share of the top cisplatin exporter from India?

Analysis Methodology